Amneal Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(81,678) | $(10,094) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
| Depreciation and amortization | 55,528 | 58,150 |
| Unrealized foreign currency loss (gain) | 1,511 | (1,987) |
| Amortization of debt issuance costs and discount | 288 | 2,058 |
| Intangible asset impairment charges | 920 | — |
| Change in fair value of contingent consideration | 100 | 2,457 |
| Stock-based compensation | 6,722 | 7,596 |
| Inventory provision | 22,923 | 25,204 |
| Other operating charges and credits, net | 1,250 | 2,047 |
| Changes in assets and liabilities: | ||
| Trade accounts receivable, net | (55,173) | 195,970 |
| Inventories | (12,200) | (22,508) |
| Prepaid expenses, other current assets and other assets | (11,708) | 29,160 |
| Related party receivables | (562) | 470 |
| Accounts payable, accrued expenses and other liabilities | 62,174 | (150,483) |
| Related party payables | 5,495 | 1,672 |
| Net cash (used in) provided by operating activities | (4,410) | 139,712 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (9,198) | (9,688) |
| Acquisition of intangible assets | (9,700) | (338) |
| Deposits for future acquisition of property, plant and equipment | (862) | (1,711) |
| Net cash used in investing activities | (19,760) | (11,737) |
| Cash flows from financing activities: | ||
| Payments of principal on debt, revolving credit facilities, financing leases and other | (63,377) | (72,659) |
| Borrowings on revolving credit facilities | 48,000 | 80,000 |
| Proceeds from exercise of stock options | 28 | — |
| Employee payroll tax withholding on restricted stock unit vesting | (7,212) | (2,022) |
| Tax distributions to non-controlling interests | (594) | (18,219) |
| Net cash used in financing activities | (23,155) | (12,900) |
| Effect of foreign exchange rate on cash | (165) | 767 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (47,490) | 115,842 |
| Cash, cash equivalents, and restricted cash - beginning of period | 99,107 | 35,227 |
| Cash, cash equivalents, and restricted cash - end of period | $51,617 | $151,069 |
| Cash and cash equivalents - end of period | $46,520 | $144,674 |
| Restricted cash - end of period | 5,097 | 6,395 |
| Cash, cash equivalents, and restricted cash - end of period | $51,617 | $151,069 |
Consolidated Statements of Cash Flows (continued)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $64,514 | $41,066 |
| Cash (paid) received, net for income taxes | $(4,567) | $3,421 |
| Supplemental disclosure of non-cash investing and financing activity: | ||
| Tax distributions to non-controlling interests | $3,777 | $11,548 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.